Abstract: Objective To compare the effects of cilostazol on cerebral arteries and cerebrovascular blood flow in secondary prevention of ischemic stroke, with those of aspirin. Methods Sixty-eight patients who had ischemic stroke during the recent 1-6 months were recruited and randomized into cilostazol or aspirin group. Cerebrovascular condition was assessed by magnetic resonance angiography (MRA) and transcranial doppler ultrasonography (TCD) at the beginning of the study and after 12-month medication. Results During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found. MRA revealed that in aspirin group, the percentages of patients experiencing aggravation and attenuation of cerebrovascular condition were 3.3% and 6.7%, respectively, while in aspirin group, they were 3.3% and 10%, respectively. Moreover, TCD revealed that 26.9% of the patients in aspirin group and 14.3% of the patients in cilostazol group experienced aggravation of cerebrovascular condition. However, the systolic peak flow velocity of the previously abnormal arteries increased by 42.9% after 12-month medication of cilostazol, which was significantly higher than that after aspirin medication (27.5%) (P = 0.04).
Introduction
Antiplatelet therapy plays an important role in secondary prevention of ischemic stroke. As an antiplatelet agent, although aspirin is widely used, the formation of drug resistance and the risk of bleeding [1.2] have limited the clinical application of aspirin. Cilostazol has been shown to significantly reduce the risk of stroke recurrence while it does not induce the intracranial hemorrhage, thus it has drawn much attention since the past few years.
In the Cilostazol Stroke Prevention Study (CSPS) [3, 4] , a randomized, double-blind, and placebo-controlled trial was conducted, involving more than 1 000 Japanese patients, who had been diagnosed with ischemic stroke during the previ- In the Trial of cilOstazol in Symptomatic intracranial Stenosis (TOSS) [5] , which is another multicenter double-blind placebo-controlled trial, 135 patients with acute symptomatic stenosis in the M1 segment of middle cerebral artery or the basilar artery are randomized to cilostazol medication (200 mg per day) or placebo for 6 months, during which all the patients also receive aspirin medication. The results have shown that cilostazol and aspirin are tolerable and the co-effect in preventing the progression of symptomatic intracranial arterial stenosis (IAS) is superior to that of aspirin mono-therapy.
However, this also fails to determine whether cilostazol is superior to aspirin in cerebrovascular restenosis prevention.
Besides the antiplatelet property, cilostazol also exerts other effects, such as vasodilation, inhibition of thrombosis, decrement of triglycerides, elevation of high density lipoprotein cholesterol, inhibition of vascular smooth muscle cell growth, and neuroprotection [6] [7] [8] [9] . It is hypothesized that cilostazol may play an important role in preventing the aggravation of cerebrovascular stenosis. Thus, the present study aims to compare the effects of cilostazol with those of aspirin on cerebral arteries and cerebrovascular blood flow in secondary prevention of ischemic stroke. 
Materials and methods

Study design
Participants
The participants in this study were 18-75 years old, and all of them had ischemic stroke (modify Rankin Scale less than 4) during the previous 1-6 months, which had been confirmed by cranial computed tomography (CT) or magnetic resonance imaging/angiography (MRI/MRA).
The patients exhibiting any of the following symptoms were excluded from the study: (1) known hemorrhagic diathesis or recent major bleeding history; (2) Besides, the transorbital approach was used for carotid siphon (C3 segment of the ICA) study, and the suboccipital approach through the foramen magnum was used for basilar artery (BA) evaluation. Both MRA and TCD were performed at the beginning of recruitment and at the end of the 12-month medication. taken, the patients were excluded. When serious adverse effects happened, participants were also dropped out as decided by a physician who did not know the drug allocation.
Clinical follow up
All the adverse effects were recorded, and their possible associations with the studied drugs were assessed. After the follow-up evaluations, the raw MRA data of the patients were gathered as graphic information, and 2 researchers who were blind to the clinical information reviewed the data using the same types of monitors and software. The extent of cerebrovascular stenosis was classified into 4 grades according to the report of Rother [10] : normal (no signal loss), mild (signal reduction: A < 50%, B ≥ 50%), moderate Aggravation of stenosis was identified by TCD as the following [5.10] : (1) the change of the waveform to an occlusive pattern; or (2) an increase in the systolic peak flow velocity (>20 cm/s) by >20% on flow-up TCD compared with baseline value. Improvement was defined as: (1) change of the occlusive waveform to a stenotic pattern; or (2) a decrease in the systolic peak flow velocity (>20 cm/s) by >20%. Five clinical vascular events (3 ischemic stroke, 1 intracerebral hemorrhage, and 1 acute coronary event) occurred in the 2 groups. There were 7 (20.5%) participants prematurely terminated in cilostazol group and 6 (17.6%) in aspirin group. Two patients in aspirin group died of acute myocardial infarction and acute pancreatitis, respectively. There were totally 3 cases of ischemic stroke recurrence, among which 2 cases were in cilostazol group and 1 in aspirin group. As listed in Table 2 , the number of premature termination was not significantly different between the 2 groups. Table 3 , the degree of arterial stenosis changed in 7 of the 60 patients (11.6%). Only 1 patient (3.3%) experienced aggravation in cilostazol group, and 1 patient in aspirin group.
Outcome measurement
Statistical analysis
Changes of cerebral arteries
The improvement was found in 2 patients (6.7%) in cilostazol group and in 3 patients (10.0%) in aspirin group. The rates of aggravation and improvement were not significiantly different between cilostazol and aspirin groups (P = 0.90).
TCD evaluations were conducted in 47 patients, and the results were similar and consistent with those of MRA. The aggravation of stenosis was detected in 3 of the total 21 patients (14.3%) in cilostazol group and 7 of 26 (26.9%) in aspirin group. Although the rate of aggravation was relatively lower in cilostazol group, there was no significant difference between the 2 groups (P = 0.40) in the rates of aggravation or improvement. As shown in Table 4 , TCD method revealed that the systolic peak flow velocity of the cerebral artery exhibited a mild decrease in aspirin group, and a mild increase in some arteries in cilostazol group after one-year medication.
However, neither group showed significant difference in the systolic peak flow velocity of the cerebral artery between the initial of medication and the end of medication (after 12 months).
According to Kwon and Sliwka's criteria [5, 10] , the change of cerebrovascular systolic peak flow velocity was further analyzed in all the patients. TCD results showed that none of the arteries exhibiting normal systolic peak flow velocity at the initial of medication deteriorated later. However, among the 153 arteries (84 in cilostazol group and 69 in aspirin group) that exhibited abnormal systolic peak flow velocity at the initial of medication, 36 (42.9%) arteries showed an increase in systolic peak flow velocity in cilostazol group and 19 (27.5%) in aspirin group. There was an significant difference in the number of these abnormal arteries between the 2 groups, but not in the number of abnormal arteries that exhibited decreasing or stationary systolic peak flow velocity (Table 5 ).
Discussion
Stroke is the leading cause of death and disability in China [11] , and also a leading cause of hospitalization in neurological department. The most common type of ischemic stroke is lacunar infarction, followed by atherothrombotic and cardioembolic infarction. The incidence, mortality, and cost of stroke may all increase with aging in Chinese population.
The strategy for secondary prevention of stroke is pri- marily focused on controling the vascular risk factors, including management of hypertension, lipid abnormalities, and smoking cessation. Antiplatelet therapy also plays an important role. The present study mainly aims to evaluate the efficacy of cilostazol, an inhibitor for phosphodiesterase-3, on cerebral arteries in the secondary prevention of ischemic stroke. Our major finding is that cilostazol is as effective as aspirin on preventing the aggravation of cerebral arteries in secondary prevention of ischemic stroke. Besides, it is more safe. Cilostazol can also increase systolic peak flow velocity of cerebral arteries, which may improve the blood supply of focal ischemia.
Meanwhile, side effects developed in the patients during the study, including headache, gastrointestinal disturbance, dizziness, bleeding, etc. Between the 2 groups, bleeding occurred more frequently in aspirin group and headache more frequently in cilostazol group. Our results suggest that cilostazol is more safe than aspirin in bleeding event and patients may benefit from the lower incidence of bleeding by using cilostazol. This result is quite consistent with a previous report [12] . Besides, the occurrence of headache may be attributed to the vasodilation effect of cilostazol, which can be avoided or attenuated by reducing the dose at the beginning.
While digital subtraction angiography (DSA) is considered to be invasive, we used MRA instead to assess the degree of stenosis and analyze the changes of cerebral artery stenosis. TCD was further conducted to confirm the reliability of MRA results. Since there are no commonly accepted TCD criteria for the classification of cerebral artery stenosis, an elevation of the systolic peak flow velocity has a good correlation with DSA, especially in moderate and severe stenosis [10] . Thus the systolic peak flow velocity detected by TCD was employed to assess the cerebral artery stenosis.
As revealed by MRA, there were no significant differences in the number of improved arteries or aggravated arteries between the 2 groups. Meanwhile, TCD results also indicate that the aggravation rate is relatively lower in cilostazol group, but with no statistical difference between the 2 groups.
We further analyzed the changes of cerebrovascular systolic peak flow velocity of all the patients between the initial and the end of medication (one year later). Of the arteries that exhibited abnormal systolic peak flow velocity at the initial of medication, cilostazol group showed more percentage with velocity increase than aspirin group did. The increase of blood velocity in cilostazol group may be due to the small-vessel dilation, which can improve the blood supply of focal ischemia. Since several studies have confirmed that cilostazol causes vasodilation of isolated and pressurized rabbit spinal arteriole [13] , we extrapolate that the elevation of the systolic peak flow in the cerebral microcirculation may be also due to the cilostazol-induced vasodilation of the arterioles feeding the central nervous system. Cilostazol has also been proved to dilate the pial arteries and inhibit the formation of thrombosis during focal ischemia in cat [14] . In a rat model of focal cerebral ischemia, cilostazol improves cerebral blood velocity (CBV) and cerebral blood flow (CBF) in the peri-infarct area [15] . Clinically, cilostazol could also reduce the risk of stroke with small-vessel etiology in the CSPS trial [4, 16] . The exact mechanisms of cilostazol in vascular smooth muscle still unknown [13] . Presumably, inhibition in phosphodiesterase-3 and the corresponding cAMP increase in smooth muscles of arterioles are involved to some extent, because phosphodiesterase-3 is strongly expressed in these cells [17] .
In the investigations of TOSS [5] , co-treatment of cilostazol and aspirin induces the aggravation of symptomatic IAS in 3 (6.7%) out of the total 45 patients, and the improvement in 11 (24.4%) patients. In aspirin group, 15 (28.8%) patients experience symptomatic IAS aggravation and 8 (15.4%) patients experience improvement. In the present study, the vascular change of stenosis is relatively lower, which may be due to the different observed stroke phases. The study of TOSS addresses the acute phase of stroke (within 2 weeks after cerebral infarction), whereas our study deals with the subacute or chronic phase of brain infarction (1-6 months after cerebral infarction). It is possible that the cerebrovascular plasticity at the acute phase may differ from that at the chronic phase, in that the cerebrovascular plasticity at the acute phase may be more obvious than that at the chronic phase. On the other hand, the patient selection in the study of TOSS may be also responsible for this difference. In the study of TOSS, all the patients have acute symptomatic stenosis in the M1 segment of middle cerebral artery or the basilar artery, while in our study, only part of the patients are detected with vascular stenosis. The third explanation for the difference is the drug management. TOSS applies co-treatment of aspirin and cilostazol, whereas our study employs aspirin monotheraphy.
And co-treatment of aspirin and cilostazol may be superior to aspirin monotheraphy in preventing the aggravation of symptomatic IAS.
However, there are 2 limitations in our study, that is, the small number of participants and the short period of the study. Further clinical trials on vascular events are required to confirm the efficacy of cilostazol on cerebrovascular restenosis prevention in ischemic stroke.
